Seven October 21 readings: older adults' reported fraud losses, a military-mortgage settlement, two merger matters and three FDA records on treatment and labeling. Reading dates, source events and unfinished outcomes stay distinct.
7 reports 0 commentary 1 connected standing files
A dated edition of the record read and filed on October 21, 2026, Arizona time. The dates and statuses below describe that reading; later developments belong in the linked archive and its correction notices.
01 / Read the record
Fraud losses and mortgage redress
Reported losses describe harm; a settlement requires compensation. Follow what each record establishes about money reaching people.
FTC report · October 19 publication2 min read · 2 source receipts
People 60 and older reported about $3 billion in fraud losses in 2025, roughly five times the 2020 total, according to the FTC's October 19 report. Investment scams accounted for more than $1 billion. The reported figures are not a population survey; separate estimates of unreported losses depend heavily on assumptions about reporting.
Why it matters
People 60 and older reported about $3 billion in 2025 fraud losses, with investment scams accounting for more than $1 billion. The report describes risks to savings and the limits of reported totals.
What to watch
The FTC directs fraud reports to ReportFraud.ftc.gov. Its estimate of overall older-adult fraud losses depends on assumptions about unreported harm.
The limit. Self-selected reports are not a population survey. Estimated losses are not a measured total, and a referral for help does not promise recovery.
How this record was read
Read October 21 Arizona time, fetched directly from the FTC with curl: the October 19 release and the report PDF, including its introduction, Consumer Sentinel analysis and methodology in section IV.A.1, and the coordination discussion in section IV.B. Raw bytes, extracted text and hash-bound receipts were saved. Limits: Sentinel reports are self-selected, not a survey; the underlying reports, cited research studies and individual enforcement dockets were not independently examined. The estimates are the FTC's calculations under alternative assumptions, not measured losses or a statistical confidence interval.
Village Capital's agreement with the Justice Department requires a $425,000 compensation fund and a separate $79,380 civil penalty over alleged violations of servicemembers' mortgage protections. DOJ identified 41 accounts in its initial review, and the agreement requires further review and payment calculations. Required deposits and compensation are obligations, not proof borrowers have received money.
Why it matters
Village Capital must establish a $425,000 compensation fund and pay a separate $79,380 Treasury penalty to resolve alleged violations of military mortgage protections.
What to watch
Payment-delivery efforts are due within thirty calendar days of receiving DOJ's final compensation determination. Required accountings distinguish checks issued from checks cashed or deposited.
The limit. The agreement resolves allegations without a court merits finding. It does not prove a fund deposit or borrower receipt, and no absolute deadline is computed from its signature pages.
How this record was read
Read October 21 Arizona time, fetched directly from DOJ: the executed agreement's allegations, compensation terms, civil penalty and reporting requirements. Limits: the press-release URL returned challenge pages to identifying curl and Python clients; no release-only claim is used. The agreement is not a court finding or a public receipt showing payments reached borrowers; no absolute deadline is computed from its signature pages.
02 / Read the record
Competition under review
A lawsuit seeks to stop a purchase. Proposed consent terms would condition another. Neither is a finding that a completed merger harmed customers.
October 19 complaint · allegations pending2 min read · 2 source receipts
The FTC and state attorneys general filed an October 19 lawsuit seeking to block PlayPower's acquisition of playground manufacturer Burke. Their complaint alleges the deal would reduce price, service, quality and innovation competition for schools, parks, churches and other buyers. These are allegations in a pending court challenge, not findings that the merger has caused harm.
Why it matters
The FTC and states allege PlayPower's purchase of Burke would reduce price, service, quality and innovation competition for schools, parks, churches and other playground buyers.
What to watch
The plaintiffs seek a permanent injunction. The complaint says the parties stipulated to a temporary restraining order, but that statement does not establish that the court entered one.
The limit. The public complaint is substantially redacted. Defendants' responses and later court orders were not read; predicted competitive harms remain the plaintiffs' allegations.
How this record was read
Read October 21 Arizona time, fetched directly from the FTC with curl: the October 19 release and public redacted complaint in case 3:26-cv-12072, including the caption, nature-of-the-case allegations, discussion of competition for sales representatives and prayer for relief. Raw bytes, extracted text and hash-bound receipts were saved. Limits: the complaint contains substantial redactions; the defendants' responses, underlying internal documents and subsequent court orders were not read. The claimed competitive harms and market shares remain the plaintiffs' allegations.
Proposed consent terms · subject to final approval2 min read · 5 source receipts
The FTC accepted proposed consent terms for Publicis's approximately $2.2 billion acquisition of LiveRamp on October 19, subject to final approval. The terms would protect competing customers' access and confidential data, with independent audits and customer protections. The agency announced a 30-day public-comment period; the proposed order is not a final adjudication of the complaint's allegations.
Why it matters
The proposed Publicis-LiveRamp order would protect competing customers' access to advertising-data services and restrict access to their confidential data, with audits and complaint protections.
What to watch
The October 19 terms have a 30-day public-comment period. The records read print no calendar closing date; filing instructions are on the FTC docket.
The limit. The order remains proposed and the matter pending. It establishes neither a completed acquisition nor prior misuse of customer data, and it does not admit the complaint's merits allegations.
How this record was read
Read October 21 Arizona time, fetched directly from the FTC with curl: the October 19 release, complete complaint, case page marked Pending, Analysis to Aid Public Comment, and the proposed order's decision, access, information safeguards, audits, mediation and term provisions. Raw bytes, extracted text and hash-bound receipts were saved. Limits: the merger agreement, Order to Maintain Assets, separately posted consent agreement and public comments were not read. No calendar comment deadline or completed acquisition is established here; the release and analysis specify a 30-day comment period. The proposal is not final and does not admit the complaint's merits allegations.
03 / Read the record
Treatment options and their limits
Two drug approvals have defined eligible patients and safety limits. Software-labeling guidance describes FDA's approach without becoming a binding new rule.
Drug approval · October 202 min read · 1 source receipt
FDA approved Hibsago on October 20 for certain adults with chronic hepatitis B who do not have cirrhosis and meet treatment and laboratory requirements. Across two trials, 24% of treated patients qualified to stop their existing medicine. The injection carries a boxed warning for serious liver reactions and low platelet counts.
Why it matters
Hibsago offers certain adults with chronic hepatitis B a treatment alongside existing antivirals, with some trial patients later meeting requirements to stop all treatment.
What to watch
Eligibility requires no cirrhosis, at least six months of antiviral therapy, suppressed virus and surface antigen at or below 3,000 IU/mL on an authorized test. FDA says regular blood tests and follow-up are needed.
The limit. The boxed warning covers serious liver reactions and low platelet counts. Trial endpoints do not mean everyone can stop medicine; no price or commercial availability date is established.
How this record was read
Read October 21 Arizona time, fetched directly from FDA: the October 20 approval announcement, including eligibility, trial endpoints and safety warnings. Limits: the prescribing information and full trial reports were not read; the announcement does not establish a price or current commercial availability.
Generic approval · October 19, announced October 202 min read · 1 source receipt
FDA's October 20 announcement says the agency approved the first generic Climara Pro patch the previous day. The once-weekly estrogen and progestogen patch is approved for specified menopause symptoms and osteoporosis prevention in women with an intact uterus. FDA identifies the manufacturer but gives no selling price or availability date.
Why it matters
The first generic Climara Pro patch gives another approved once-weekly estrogen-and-progestogen option for specified menopause symptoms and osteoporosis prevention in women with an intact uterus.
What to watch
Read the stated contraindications and adverse reactions. FDA directs availability questions to the manufacturer; its October 20 release says approval was the previous day.
The limit. Therapeutic equivalence does not establish a patient's eligibility or price. The announcement gives no measured savings or availability date, and the product label was not read.
How this record was read
Read October 21 Arizona time, fetched directly from FDA: the October 20 announcement, which says approval occurred yesterday, placing it on October 19. Read indications, contraindications, adverse reactions and manufacturer availability instruction. Limits: the product labeling was not read; no selling price, measured savings or commercial availability date is established.
Final guidance · nonbinding; October 21 notice2 min read · 3 source receipts
FDA released final guidance on October 20 about software disseminated by or on behalf of prescription-drug sponsors, followed by an October 21 Federal Register notice. It addresses app content, prescribing information and submissions for FDA review. The guidance is nonbinding, and the notice permits comments at any time rather than setting a new closing date.
Why it matters
The guidance addresses information that prescription-drug companion software shows patients, caregivers and clinicians, and when software belongs in prescribing information or submissions for FDA review.
What to watch
FDA released the guidance October 20; the Federal Register notice printed October 21. Comments on docket FDA-2023-D-2482 may be submitted at any time, with separate confidential-paper instructions.
The limit. The guidance is not binding on FDA or the public and does not approve every app. The report reads FDA's release and published notice, not the separate full guidance.
How this record was read
Read October 21 Arizona time, fetched directly from FDA and govinfo: FDA's October 20 release and the published October 21 Federal Register notice, pages 66561-66563; Register API metadata confirmed publication. Limits: the separate full guidance was not read. This reports the release and notice, not approval of an individual app or a binding new rule.
04 / Keep reading
Into the standing files
These dossiers contain source records also cited by the reports above. A shared record establishes this reading connection; it does not imply an allegation or a relationship between people.
